title: Therapeutical effects of PPAR agonists assessed by biomarker modulation.
abstract: The metabolic syndrome is defined as the clustering of cardiovascular risk factors, such as glucose intolerance, hyperinsulinemia, dyslipidemia, coagulation disturbances and hypertension. Activators of the nuclear receptors peroxisome proliferator-activated receptors (PPARs) modulate several of the metabolic risk factors pre-disposing to atherosclerosis. Fibrates are hypolipidemic drugs operating through activation of PPARalpha, whereas glitazones are insulin sensitizers activating PPARgamma. In addition, these drugs exert pleiotropic and anti-inflammatory actions. This review will focus on the different effects of fibrates and glitazones, as measured by biomarker modulation, on the development of atherosclerosis and cardiovascular disease.
authors.affiliation: UR 545 INSERM, Institut Pasteur de Lille, Université de Lille 2, Lille, France. giulia.chinetti@pasteur-lille.fr
authors.forename: G
authors.initials: G
authors.lastname: Chinetti-Gbaguidi
authors.forename: J-C
authors.initials: JC
authors.lastname: Fruchart
authors.forename: B
authors.initials: B
authors.lastname: Staels
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy / Q000517:prevention & control*; D015415:Biomarkers; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control; D002995:Clofibric Acid / Q000494:pharmacology; D006801:Humans; D007249:Inflammation; D024821:Metabolic Syndrome / Q000473:pathology; D047493:PPAR alpha / Q000819:agonists*; D047495:PPAR gamma / Q000819:agonists*; D045162:Thiazolidinediones / Q000494:pharmacology
chemical_list: D015415:Biomarkers; D047493:PPAR alpha; D047495:PPAR gamma; D045162:Thiazolidinediones; D002995:Clofibric Acid